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Aims Patients with atrial ﬁbrillation (AF) consider the related symptoms disruptive to their quality of life (QoL). This study
aimed to evaluate the impact of the control of symptomatic paroxysmal AF (PAF) on QoL.
Methods
and results
Patients with symptomatic PAF were treated for 48 weeks with open-label ﬂecainide acetate controlled release (Flec
CR). Quality of life was assessed by SF-36 and Atrial Fibrillation Severity Scale scores at baseline, Week 12 (W12),
W24, and W48. Of the 229 treated patients, 217 were analysed for QoL (123 with controlled and 94 with uncon-
trolled symptomatic PAF at inclusion). The controlled group had a similar or better QoL (SF-36) at baseline com-
pared with a reference population (signiﬁcantly better for: physical functioning, bodily pain, and physical component).
The uncontrolled group had an inferior QoL (signiﬁcantly worse for: role physical, general health, vitality, role emotional,
social functioning, mental health, and mental component). When treated with Flec CR, the controlled group baseline
QoL scores were maintained and the uncontrolled group scores were improved to a level comparable to the con-
trolled group scores. Safety ﬁndings reﬂect the known clinical safety proﬁle of ﬂecainide acetate.
Conclusion In this study, patients with uncontrolled symptomatic PAF at baseline had an inferior QoL to those with controlled
symptomatic PAF. Following treatment with controlled-release ﬂecainide acetate, their QoL improved to a level com-
parable to controlled patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Atrial ﬁbrillation (AF), whether paroxysmal (PAF) or persistent, is a
chronic disorder, and recurrence is likely at some point in most
patients with AF.
1 Stroke as well as functional impairments and
cardiac failure are the well-known consequences of AF.
1 However,
interventions such as antiarrhythmic drugs, electrical cardioversion,
orcatheterablationforterminatingorsuppressingAFhavenotbeen
showntopreventstrokeorreducemortality.
2–4Ontheotherhand,
patients with AF also experience a broad range of symptoms which
adversely affect their quality of life (QoL).
5
The impact of AF on QoL is strongly inﬂuenced by the segment
of the population that is concerned, as some patients are entirely
asymptomatic.
6 One study
7 shows that the majority of patients
with PAF consider the dysrhythmia disruptive to their life;
however, QoL literature speciﬁc to PAF patients is sparse.
In patients with recurrent arrhythmias, radiofrequency catheter
ablation of the atrioventricular (AV) node and pacemaker insertion
improved QoL
8 as determined by the SF-36 health status question-
naire
9 and the disease-speciﬁc Symptom Checklist Frequency and
Severity Scale.
10 However, the relative impact of AF among patients
who have received little prior treatment to restore or maintain sinus
rhythm is not clear.
11 In a study of patients with symptomatic AF,
12
QoL improved after pharmacological treatment of their ailment, and
patients in whom therapy prevented AF recurrence experienced the
greatest beneﬁt. The latter study also suggests that measures of
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doi:10.1093/europace/euq007subjective well-being are important adjunct measures, in addition to
objective measures of disease severity (e.g. frequency or duration of
AF attacks). Other studies have conﬁrmed a meaningful improvement
of QoL after both pharmacological and non-pharmacological AF
therapies.
12–15 Thus, one of the primary goals of rhythm control
interventions should be to control symptoms and improve QoL.
6,16
Flecainide acetate, a Class IC antiarrhythmic used as a preventive
treatment,hasbeenshowntosigniﬁcantlydecreasetheincidenceof
PAFepisodes,withagoodsafetyproﬁle.
17–25Twomarketedformu-
lations of ﬂecainide acetate exist. The ﬁrst is an immediate-release
formulation (Flec IR) to be taken twice a day, the second is a
once-a-day controlled-release formulation (Flec CR).
26
The primary objective of the present study was to evaluate the
impact of the control of symptomatic PAF on QoL. A composite
efﬁcacy and safety criterion of ‘clinical success’ was also evaluated
as a secondary endpoint.
Methods
Ethics
This study was conducted in compliance with the ethical principles of
the revised Declaration of Helsinki (Somerset West, Republic of South
Africa, 1996). Local independent Ethics Committees approved the
study protocol and the patients provided informed consent prior to
study entry.
Patients
Patients presenting with documented symptomatic PAF (arrhythmia
terminating spontaneously) either controlled (deﬁned a priori in the
protocol as no more than one symptomatic PAF episode per 6
months) or uncontrolled (two or more symptomatic PAF episodes
per 6 months) were considered for study eligibility. During the
study, an issue with the above deﬁnition was identiﬁed: patients under-
going a treatment modiﬁcation within a few months of inclusion and
experiencing no symptomatic PAF episodes since the modiﬁcation
were being classiﬁed as uncontrolled at inclusion based on sympto-
matic PAF episodes in the last 6 months but prior to the treatment
modiﬁcation. The deﬁnition was therefore revised to more appropri-
ately classify such patients. In particular, patients having undergone a
PAF treatment modiﬁcation in the last 1–6 months prior to inclusion
were deﬁned as controlled if they had no symptomatic PAF episodes
occurring under the last therapeutic strategy or uncontrolled if they
had at least one symptomatic PAF episode.
Since it was considered that sites would more easily recruit con-
trolled patients and in order to ensure more than one-third of
recruited patients were uncontrolled at inclusion, each investigator
was encouraged to recruit one uncontrolled patient for one controlled
patient. Patients of either sex were included in the study if they met the
following criteria: aged 18 to ,80 years; in sinus rhythm at the time of
inclusion; who had experienced symptomatic AF episodes of 1 min to
72 h, based on the history of at least two symptomatic PAF episodes,
at least one of which was documented by electrocardiography (ECG)
and/or Holter; requiring antiarrhythmic therapy in the investigator’s
judgement; with left ventricular ejection fraction (LVEF) of at least
40% documented by ultrasonography; and women of childbearing
potential had to use a reliable method of contraception. Those
patients exhibiting the following criteria were not included: intolerance
and/or failure of previous therapy with Flec IR; severe symptoms
(syncope and ischaemic angina) during episodes of arrhythmia;
coronary heart disease and/or history of myocardial infarction; conges-
tive heart failure [New York Heart Association classes II, III, and IV];
history of arrhythmia other than PAF; paroxysmal supraventricular
tachycardia or atrial ﬂutter unless ablated; sinus dysfunction or atrial
disease (bradytachycardia syndrome); heart rate ,45 b.p.m.; second-
or third-degree AV block; right bundle branch block associated with
left hemiblock or complete left bundle branch block; implanted pace-
maker; renal failure; decompensated cirrhosis; signiﬁcant extracardiac
or systemic disease susceptible of interfering with assessment of QoL.
Design
This international, open-label study was conducted from September
2003 until September 2005 by 49 cardiologists from 47 cardiology
practices (8 hospitals, 4 private hospitals, 1 cardiology centre, and 34
private practices) in France, Belgium, and Italy.
All patients were to be treated with Flec CR over a 48-week period.
Patients were classiﬁed as having either controlled or uncontrolled
symptomatic PAF at inclusion. Depending on their previous anti-
arrhythmic treatment, patients were managed as follows: (i) patients
not exposed to Flec IR at inclusion entered a 2-week titration
period starting with Flec CR 100 mg once a day that was increased
to 200 mg from Day 8 onwards provided that the QRS duration was
,140 ms and had not increased by  25% from baseline and that
there were no tolerability issues; (ii) patients under Flec IR at inclusion
were switched to the equivalent daily dose of Flec CR for 48 weeks
without titration. Follow-up visits were scheduled for all patients at
Week 12 (W12), W24, and W48. Study data were reported in
paper case report forms designed according to the study protocol.
On the basis of pre-deﬁned safety and efﬁcacy criteria, doses of Flec
CR could be increased to a maximum of 200 mg per day or reduced by
50 mg per day to a minimum of 100 mg per day, where applicable.
All Classes I–III antiarrhythmics were washed out before starting
Flec CR. Amiodarone as a preventive treatment of PAF had to have
been interrupted for at least 4.5 months before inclusion in the
study. Previous use of amiodarone for the purpose of cardioversion
was allowed, provided treatment duration was limited to a maximum
of 8 days. The ongoing use of beta-blockers, digoxin, or calcium antag-
onists was permitted, provided daily doses used before the start of Flec
CR were kept constant throughout study treatment.
Quality of life
A generic and a disease-speciﬁc self-administered QoL questionnaires
were ﬁlled in by the patients in their own language (French for France,
French or Dutch for Belgium, and Italian for Italy) at baseline, W12,
W24, and W48.
To assess the primary endpoint of QoL, the generic Medical Out-
comes Study 36-Item Short-Form Health Survey (MOS SF-36)
9 was
used. The MOS SF-36 provides eight subscale measures of QoL
based on 35 of the 36 items in the survey: physical functioning (10
items scored 1–3), role limitations due to physical problems (role
physical, 4 items scored 1–2), bodily pain (2 items scored 1–5 and
1–6, respectively), general health (5 items scored 1–5), vitality (4
items scored 1–6), role limitations due to emotional problems (role
emotional, 3 items scored 1–2), social functioning (2 items scored
1–5), and mental health (5 items scored 1–5). Two summary
scores, mental component scale and physical component scale, were
computed by linear combinations of the eight subscale measures.
The Atrial Fibrillation Severity Scale (AFSS, Parts A, B, and C)
10 was
also used to assess QoL. At baseline, W12, W24, and W48, patients
completed the disease-speciﬁc self-administered questionnaire to
assess well-being and bothering symptom frequency via Question 4
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patients were also asked AFSS Part A Questions 5–8 pertaining to
AF burden. AFSS Part B was completed by the investigator at baseline
to further characterize PAF history.
The ‘clinical success’ composite safety and efﬁcacy criterion was
deﬁned as follows: patient alive; without pharmacological or electrical
cardioversion; with sinus rhythm maintained (not more than one docu-
mented AF per 24-week period); still receiving Flec CR; with QRS dur-
ation ,140 ms and change from baseline ,25%; and with LVEF of at
least 35%. Patients not fulﬁlling all of these criteria for ‘clinical success’
were considered as clinical failures. Other efﬁcacy endpoints were the
time to ﬁrst PAF recurrence objectively documented by ECG or sub-
jectively documented by inquiry and comments recorded on the
patient’s diary.
Cardiac safety was assessed based on the incidence of proarrhyth-
mic effects (worsening PAF and/or occurrence of atrial ﬂutter or of
paroxysmal supraventricular tachycardia not previously diagnosed
and/or occurrence of a clinically signiﬁcant ventricular arrhythmia in
the absence of the known history of ventricular arrhythmia), ECG
changes (mostly QRS and QTc changes), and signs of cardiac failure
(clinical examination and left ventricular function by ultrasonography).
Statistical analyses
Study analysis data sets were deﬁned as follows. The safety data set
included all patients who took at least one capsule of
controlled-release ﬂecainide acetate after study inclusion. The
intention-to-treat (ITT) efﬁcacy data set included all patients from
the safety data set except for those treated with Flec IR who were
not controlled at inclusion (exclusion criterion). The QoL baseline
and post-baseline data sets excluded patients with missing baseline
SF-36 or control status data. Any missing post-baseline QoL data for
patients in the QoL post-baseline data set were extrapolated using
the last observation carried forward (LOCF) method for analysis
purposes.
The score of each subscale of the SF-36 was calculated as the mean
of the items, except in the case where more than half of the items
were missing, in which case, the subscore was considered as missing.
The physical component and mental component summary scores
were calculated as the linear combination of the eight standardized
[mean ¼ 0, standard deviation (SD) ¼ 1] subscores. Each summary
score was then transformed by multiplying by 10 and adding 50 in
order to be compared with scores issued from a reference population
with mean 50 and SD 10. The reference population was derived from
national surveys representative in terms of age and gender.
16,27 The
process matched each treated study patient with a random sample
of country/language-, gender-, and age-matched subjects from a
general reference population.
Controlled and uncontrolled patients were compared with the
reference population for SF-36 scores at baseline, W24, and W48
by paired t-tests. Complementary analyses were stratiﬁed by
country/language, with age and gender as covariates. Adjustments
were made for the multiplicity of comparisons. The robustness of
the results was assessed using a non-parametric analysis of covariance
(ANCOVA). AFSS scores [Part A (4) and Part C (1–7)] were analysed
and compared between the pre-deﬁned analysis subgroups using a
Wilcoxon test.
Clinical failure was analysed globally and in terms of time to clinical
failure using the Kaplan–Meier time-to-event method. Time to ﬁrst
PAF recurrence was also analysed. Cox’s proportional hazards
models were used to assess the relationship between the difference
from baseline to end of study for each QoL score and (i) clinical
failure and (ii) ﬁrst PAF recurrence.
It was considered necessary to enrol 240 patients (assuming 15% of
the patients would be non-evaluable) in order to achieve 95% power
at a two-sided type I error rate of 5% for comparisons of SF-36 phys-
ical and mental health summary measures between patient subgroups
and the reference population. It was considered that half of the SD of
the reference population (SD ¼ 10) would be a perceptible variation
(medium effect size
28).
Results
Of the 230 patients enrolled in the study, 229 were treated (the
patient excluded from the safety data set had no treatment data
and no adverse reactions reported). The baseline control status
of ﬁve patients was missing and ﬁve other patients had missing
SF-36 data at baseline; these patients were excluded from the
QoL baseline data set (219 patients: 155 French, 22 French-
speaking Belgians, 20 Dutch-speaking Belgians, and 22 Italians).
Two patients were excluded from post-baseline analyses due to
their failure to satisfy the major entry criterion of control under
Flec IR at inclusion. In particular, the ITT efﬁcacy data set was com-
prised of 227 patients: 126 controlled (100 of whom were
switched from Flec IR at inclusion); 96 uncontrolled; and 5
unknown status (1 of whom was switched from Flec IR at
inclusion). The QoL post-baseline data set was comprised of 217
patients: 123 controlled and 94 uncontrolled.
Patient characteristics at baseline
Demographic and main baseline characteristics of the safety data
set according to symptomatic PAF control at inclusion are sum-
marized in Table 1. Of the ﬁve patients with missing control
status, three were male and two were female. They had a
median time since PAF diagnosis of 0.1 months and four of the
patients had a median time since ﬁrst symptomatic PAF episode
of 1.7 months. One was exposed to FLEC IR at inclusion; four
were not.
Differences in age and gender were not statistically different
between the two subgroups. Time since ﬁrst symptomatic PAF
episode was much shorter in uncontrolled compared with con-
trolled patients, as shown in particular by the percentages of
patients with a time shorter than 6 months (54.2 vs. 5.8%, respect-
ively) and conversely by the percentages of patients with time
between 12 and 60 months (17.7 vs. 46.7%) or at least 60
months (18.8 vs. 35.0%).
Sixteen patients in the controlled group were diagnosed with
PAF (according to the study requirement of two symptomatic
PAFs with at least one documented by ECG and/or Holter) in
the last 6 months prior to inclusion. However, only seven of
them had experienced their ﬁrst symptomatic PAF episode
within the last 6 months. These seven patients were included in
the controlled group because they had started treatment for
PAF following several symptomatic PAF episodes at least 1
month prior to inclusion and had experienced no symptomatic
PAF episodes since treatment instauration.
Overall, the most frequent symptoms accompanying PAF were
palpitations (85.2% of patients), fatigue (31.0%), respiratory dis-
orders (20.5%), and chest pain (11.8%). Dizziness, lipothymia,
and weakness were reported by ,10% of the patients.
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Table 1 Demographic and other baseline characteristics of the patients (safety data set)
Parameter Total (n 5 229)
a Controlled (n 5 126) Uncontrolled (n 5 98)
Age (years)
Mean (SD) 64.6 (12.0) 65.6 (11.3) 63.2 (13.0)
Range 21.0–87.0 26.0–84.0 21.0–87.0
Gender, n (%)
Male 142 (62.0) 81 (64.3) 58 (59.2)
Female 87 (38.0) 45 (35.7) 40 (40.8)
Weight (kg)
Mean (SD) 78.4 (16.1) 79.3 (17.0) 77.1 (15.3)
Range 46.0–199.0 46.0–199.0 47.0–120.0
BMI (kg/m
2)
Mean (SD) 27.1 (4.7) 27.2 (4.6) 26.8 (4.9)
Range 18.0–52.3 18.0–52.3 18.3–48.1
Time since ﬁrst symptomatic PAF (months)
Missing 9 6 2
Mean (SD) 46.8 (60.6) 56.0 (53.5) 37.1 (67.8)
Range 0.0–303.6 1.1–303.6 0.0–275.1
,1 month, n (%) 36 (16.4%) 0 (0.0%) 34 (35.4%)
1–3 months, n (%) 15 (6.8%) 3 (2.5%) 12 (12.5%)
3–6 months, n (%) 11 (5.0%) 4 (3.3%) 6 (6.3%)
6–12 months, n (%) 24 (10.9%) 15 (12.5%) 9 (9.4%)
12–60 months, n (%) 74 (33.6%) 56 (46.7%) 17 (17.7%)
 60 months, n (%) 60 (27.3%) 42 (35.0%) 18 (18.8%)
Time since PAF diagnosis (months)
Mean (SD) 40.6 (57.6) 51.4 (53.4) 28.7 (61.3)
Range 0.0–303.6 0.1–303.6 0.0–275.1
,1 month, n (%) 61 (26.6) 5 (4.0) 53 (54.1)
1–3 months, n (%) 10 (4.4) 6 (4.8) 4 (4.1)
3–6 months, n (%) 10 (4.4) 5 (4.0) 4 (4.1)
6–12 months, n (%) 24 (10.5) 16 (12.7) 8 (8.2)
12–60 months, n (%) 71 (31.0) 54 (42.9) 16 (16.3)
 60 months, n (%) 53 (23.1) 40 (31.7) 13 (13.3)
Mean duration (h:min/year)
Missing 26 17 6
Mean (SD) 17:22 (37:32) 16:40 (24:52) 18:32 (48:51)
Range 0:01–336 0:01–120 0:01–336
Left ventricular ejection fraction (%)
Missing 5 3 2
Mean (SD) 67.3 (8.4) 67.5 (8.6) 66.7 (8.0)
Range 40.0–90.0 40.0–90.0 47.0–86.0
Diabetes, n (%) 16 (7.0) 10 (8.0) 6 (6.1)
Hypertension, n (%)
(SBP   140 and/or DBP   90 mmHg)
96 (41.9) 52 (41.3) 41 (41.8)
Treated for PAF in last 6 months, n (%) 166 (72.5) 119 (94.4) 46 (46.9)
Flec IR exposure at inclusion, n (%) 103 (45.0) 100 (79.4) 2 (2.0)
Electrical cardioversion, n (%) 38 (16.6) 28 (22.2) 9 (9.2)
Pharmacological cardioversion, n (%) 121 (52.8) 69 (54.8) 52 (53.1)
Country/language, n (%)
France/French 163 (71.2) 90 (71.4) 70 (71.4)
Belgium/French 22 (9.6) 12 (9.5) 10 (10.2)
Belgium/Dutch 21 (9.2) 12 (9.5) 8 (8.2)
Italy/Italian 23 (10.0) 12 (9.5) 10 (10.2)
aFive unknown control status; SD, standard deviation; PAF, paroxysmal atrial ﬁbrillation.
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A comparison of the baseline SF-36 scores of controlled patients
to their matched reference population showed that their QoL
scores were signiﬁcantly better for the physical functioning sub-
scale, the bodily pain subscale, and the physical component
score. The other SF-36 scores showed non-statistically signiﬁcant
differences that favoured the controlled group for all scores
except for the role emotional and mental health scores, and con-
sequently the global mental component score, which favoured the
reference population. For the uncontrolled group, all of the 10
QoL scores were worse compared with the matched reference
population, of which 7 differences were statistically signiﬁcant.
The relationship between uncontrolled symptomatic PAF and
inferior QoL impacted the mental scores (signiﬁcantly worse for
role emotional, social functioning, mental health, and mental com-
ponent) more than the physical scores, although the role physical
score, which reﬂects work and daily activities, and the mixed
general health and vitality scores were also signiﬁcantly worse
for uncontrolled patients compared with the reference population.
The difference of 4.82 for the global mental component score in
the uncontrolled group corresponds to an inﬂuence of non-
control of AF on QoL close to half the SD (4.82/10.91 ¼ 0.44),
which can be considered as a medium effect size.
28 Mean differ-
ences in baseline SF-36 scores are presented by control group in
Table 2.
The analysis of the differences between the controlled and the
uncontrolled groups in baseline SF-36 scores and changes from
baseline at W12, W24, and W48 are presented in Table 3. The
differences were mostly positive at baseline (indicating worse
QoL in the uncontrolled group, and reaching statistical signiﬁcance
for the general health and vitality scores and for the mental com-
ponent score), then mostly negative for changes from baseline at
the subsequent time points, indicating a greater improvement of
QoL under Flec CR treatment in the uncontrolled group. The
most signiﬁcant results were obtained at W24, and the effect
was maintained at W48. Patients entering the trial under Flec IR,
who represented 80% of the controlled patients, had their QoL
maintained when switched to Flec CR.
The mean well-being score (SD) at baseline as assessed from
Question 4 of AFSS Part A was 6.7 (2.0) in the uncontrolled
group compared with 7.2 (1.5) in the controlled group. This
score did not change signiﬁcantly throughout the study. The
total AFSS score, calculated as the sum of scores for Questions
1–7 of AFSS Part C was assessed at baseline, W12, W24, W48,
and at end of study. As expected, the mean score at baseline
was higher for uncontrolled patients compared with controlled
patients. Still higher in the uncontrolled group at W12, it then
became similar to that of the controlled group at W24 and was
maintained at the same level in both groups thereafter (Table 4).
These results are consistent with those obtained with the SF-36
questionnaire.
Efﬁcacy
The clinical success rate was similar in the controlled and uncon-
trolled groups with, respectively, 89 of 126 (70.6%) and 66 of 96
(68.8%) patients classiﬁed as successes. The other 67 patients
failed for one or more of the following reasons: ‘pharmacologi-
cal/electrical cardioversion’, 7 of 37 and 4 of 30 for the controlled
and uncontrolled groups, respectively; ‘two or more documented
PAF per 24-week period’, 1 of 37 and 2 of 30; ‘withdrawn for treat-
ment inefﬁcacy/safety reasons, for non-compliance or for death’,
24 of 37 and 22 of 30; and ﬁnally ‘withdrawn due to delta QRS
 25 or duration  140’, 11 of 37 and 12 of 30, respectively. No
patients failed for ‘LVEF ,35%’.
Of the 158 patients (69.8%) who were clinical successes, 153
(67.4%) completed the study and 5 (2.2%) were withdrawn from
the study for reasons not related to efﬁcacy, safety, or non-
compliance. The latter ﬁve patients were right censored at the
end of treatment (or end of study if end of treatment was
missing) for time-to-event analyses. Time to event was similar in
the controlled and uncontrolled groups. The Cox proportional
hazards analysis of the relationship between clinical failure and
each SF-36 score difference from baseline to end of study
................................................................................
Table 2 Mean differences (reference 2 study
subgroup) in baseline SF-36 scores for controlled and
uncontrolled patients (QoL baseline data set)
Variable n Mean (95% CI) SD P-value
Controlled (N ¼ 123)
Physical
functioning*
122 24.71 (29.15, 20.27) 24.76 0.0378
Role physical 121 20.23 (27.09, 6.63) 38.10 0.9473
Bodily pain* 121 24.75 (28.89, 20.60) 23.01 0.0251
General health 119 21.48 (24.92, 1.96) 18.93 0.3957
Vitality 120 20.77 (24.01, 2.46) 17.89 0.6373
Role emotional 119 0.91 (25.54, 7.37) 35.57 0.7797
Social
functioning
121 20.28 (23.97, 3.41) 20.52 0.8812
Mental health 120 2.51 (20.58, 5.59) 17.05 0.1099
Mental
component
115 1.21 (20.41, 2.83) 8.76 0.1414
Physical
component*
115 22.01 (23.87, 20.15) 10.06 0.0346
Uncontrolled (N ¼ 96)
Physical
functioning
96 2.65 (22.34, 7.65) 24.65 0.2947
Role physical* 93 12.89 (4.49, 21.29) 40.78 0.0030
Bodily pain 96 0.43 (25.15, 6.02) 27.56 0.8784
General health* 96 6.43 (2.13, 10.72) 21.20 0.0038
Vitality* 96 8.19 (4.12, 12.27) 20.12 0.0001
Role emotional* 96 12.75 (4.60, 20.90) 40.23 0.0025
Social
functioning*
96 6.71 (1.84, 11.58) 24.03 0.0074
Mental health* 96 7.27 (3.40, 11.15) 19.12 0.0003
Mental
component*
93 4.82 (2.58, 7.07) 10.91 ,0.0001
Physical
component
93 1.41 (20.89, 3.70) 11.15 0.2267
Higher subscale scores indicated better QoL. N, total number of patients; CI,
conﬁdence interval; SD, standard deviation.
*Statistically signiﬁcant at the 0.05 level.
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Table 3 Summary of controlled and uncontrolled subgroup scores for baseline, W12, W24, and W48 in SF-36 scores (QoL post-baseline data set)
Variable Baseline
Day 0 Week 12 Week 24 Week 48
Controlled LS
mean
Uncontrolled LS
mean
P-value Controlled LS
mean
Uncontrolled LS
mean
P-value Controlled LS
mean
Uncontrolled LS
mean
P-value Controlled LS
mean
Uncontrolled LS
mean
P-value
Physical Functioning 79.4 75.1 0.13 0.1 2.3 0.29 21.3 3.4 0.08 0.2 4.9 0.08
Role Physical 71.3 61.4 0.06 3.2 8.4 0.26 1.3 15.5 0.02* 2.0 10.4 0.23
Bodily Pain 72.0 68.2 0.23 20.1 3.2 0.49 22.6 0.5 0.49 20.4 2.9 0.49
General Health 64.1 57.6 0.01* 20.5 4.0 0.03* 21.5 5.8 0.002* 21.7 5.2 0.003*
Vitality 58.8 50.8 0.001* 0.0 3.7 0.08 21.1 5.5 0.004* 20.1 4.5 0.07
Social Functioning 78.7 73.3 0.08 3.3 3.6 0.90 1.5 5.2 0.34 2.1 6.0 0.33
Role Emotional 73.6 66.5 0.16 2.6 9.4 0.14 20.5 12.5 0.02* 20.5 10.2 0.09
Mental Health 65.6 61.7 0.08 1.1 3.5 0.22 1.5 5.1 0.10 1.1 3.5 0.19
Mental Component scale 48.9 46.0 0.029* 0.8 2.3 0.16 0.7 3.3 0.04* 0.3 2.8 0.09
Physical Component scale 47.7 45.6 0.10 0.1 1.4 0.22 21.1 1.8 0.03* 20.1 2.0 0.10
Results are expressed in least square means (P-value) adjusted for age, country, and language in country. Missing post-baseline data were extrapolated using the LOCF method. P-values for post-baseline differences are adjusted for multiplicity
using a step-down permutation procedure taking into account correlations among hypothesis tests.
*Statistically signiﬁcant at the 0.05 level.
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9Similar trends were seen in the 23 patients (12 controlled, 10
uncontrolled, and 1 unknown) who experienced at least one docu-
mented PAF recurrence.
Cardiac safety
Fifteen events related to proarrhythmic effects were observed in
14 of 229 (6.1%) patients. They included atrial ﬂutter (six patients),
bradycardia (three patients), right bundle branch block (two
patients), and sudden death (one patient). The other three
events were not reported by the investigator but were documen-
ted as adverse events related to proarrhythmic effects by the
sponsor after a post-study review of the ECG data. The sudden
death of a 77-year-old male with uncontrolled symptomatic PAF
at inclusion, who had a 10-year history of high blood pressure
and venous insufﬁciency and a recent aortic regurgitation, was con-
sidered probably not related to the study drug by the investigator.
In the absence of sufﬁcient information to deﬁnitely exclude a
proarrhythmic effect of Flec CR, the serious adverse event was
documented by the sponsor as possibly related to the study drug.
A QRS duration  140 ms or an increase in QRS by 25% or
more was noted for 2 of 109 (1.8%) patients by W12 in the con-
trolled group vs. 7 of 83 (8.4%) in the uncontrolled group. The
mean (SD, median) QRS change at the end of the study was
1.1% (17.9, 0.0%) for the controlled group compared with 4.7%
(15.1, 2.6%) for the uncontrolled group. At the end of the study,
QTc was prolonged to over 440 ms in 15 of 106 (14.2%) con-
trolled patients with a baseline QTc interval of no more than
440 ms compared with 15 of 80 (18.8%) uncontrolled patients.
Comparing patients based on Flec IR status at inclusion (Flec IR
vs. no Flec IR), at the end of the study, QTc was prolonged to
over 440 ms in 10 of 88 (11.4%) Flec IR patients with a baseline
QTc interval of no more than 440 ms compared with 20 of 101
(19.8%) no Flec IR patients.
General safety
A total of 146 of 229 (63.8%) patients experienced at least one
treatment emergent adverse event during the study and 23
serious adverse events were reported in 20 (8.7%) patients (includ-
ing one death described earlier). Gastrointestinal disorders (20.5%
of the patients), nervous system disorders (19.7%), musculoskeletal
disorders (18.8%), infections and infestations (16.2%), general dis-
orders (13.1%), cardiac disorders (12.7%), and vascular disorders
(11.4%) were the most common system organ classes
(MedDRA) of adverse events in the study. Thirty-ﬁve (15.3%)
patients experienced events which were thought by the investi-
gator to be possibly or probably related to study treatment and
7.9% of the patients were withdrawn from the study due to the
occurrence of an adverse event.
Discussion
In this study, patients with uncontrolled symptomatic PAF, unlike
patients with controlled symptomatic PAF, had an inferior per-
ceived health-related QoL when compared with a country/
language-, gender-, and age-matched general reference population.
These patients showed an inferior QoL in all eight SF-36 subscales,
with signiﬁcantly worse scores for role physical, general health,
vitality, role emotional, social functioning, and mental health and
a signiﬁcantly worse summary score for mental health. The
SF-36 is the most widely validated generic instrument available
to measure perceived health-related QoL and has been used in a
number of studies. The present results are in agreement with
several published studies including an international study of 152
patients with PAF (60.5%) or persistent (39.5%) AF
5 and a large
inspection cohort of 963 newly diagnosed patients in North
America with PAF (4.0%) or persistent (96.0%) AF.
16 The distinc-
tive feature of the present study is the focus on PAF which may
disable QoL in a different way to persistent or permanent AF.
Indeed PAF can concern a different population regarding associ-
ated cardiac disease and can be perceived differently due to the
paroxysms. In this study, extracardiac co-morbidity could have
impacted the SF-36 result
6 as it is a generic instrument; however,
the AF-speciﬁc scale conﬁrms the difference at baseline between
controlled and uncontrolled patients. Furthermore, the study
population had few co-morbid health conditions.
Following treatment with controlled-release ﬂecainide acetate,
SF-36 scores showed an improvement in the QoL of uncontrolled
patients, with maximum effect obtained at W24 and maintenance
of improvement at W48. Baseline QoL levels were maintained for
controlled patients. Results of a sensitivity analysis using a country/
language-, gender- and age-adjusted non-parametric ANCOVA on
SF-36 scores validate these ﬁndings. Previous studies have shown
that QoL improves with a variety of AF control therapies, whether
pharmacological for rate or rhythm control in persistent AF
29 and
for rhythm control in studies investigating amiodarone, propafenone,
or sotalol in persistent AF,
12,15 or non-pharmacological, such as
catheter ablation.
7
Total AFSS scores illustrated a marked improvement of symp-
toms in the uncontrolled group at W12. Scores then continued
to improve between W12 and W24 and were maintained at this
level between W24 and W48. Flecainide acetate is known to sig-
niﬁcantly decrease the incidence of PAF episodes and the relation-
ship between AFSS improvement and decrease/disappearance of
AF recurrence has been previously reported in the CTAF.
30
Clinical success, based on a composite safety and efﬁcacy end-
point, was observed in 70% of the patients with no difference
between the uncontrolled and the controlled groups. There was
a signiﬁcant relationship between clinical failure and the SF-36
scores physical functioning (P ¼ 0.01), bodily pain (P ¼ 0.001),
and physical component (P ¼ 0.0003).
The HRs presented above indicate a 1.9% reduction in risk is
associated with a decrease of one point in both the bodily pain
and physical functioning subscales of the SF-36; and a 5.4%
reduction in risk per single point in the physical component score.
Physical functioning and physical component scores were also
signiﬁcantly related to the time to ﬁrst PAF recurrence (P ¼
0.005 and P ¼ 0.02, respectively).
The time-to-ﬁrst-PAF-recurrence HRs presented above indicate
a 1.9% reduction in risk is associated with a decrease of one point
in the physical functioning subscale; and a 3.3% reduction in risk
per single point in the physical component score.
Since one of the main goals of maintenance therapy is suppres-
sion of symptoms and the most beneﬁcial therapies for patients
prevent AF recurrence, this study was designed to investigate
L. Gue ´don-Moreau et al. 640the impact of the control of symptomatic PAF on QoL. Post-
baseline analyses investigating the relationship between AF
burden and QoL are beyond the scope of this study.
Caution should be taken when interpreting study results due to
the fact that patient control status is deﬁned based on symptoms
reported by the patient. Furthermore, there is a signiﬁcant differ-
ence between the two control status subgroups in the duration
of illness at inclusion (54.2% of uncontrolled patients experienced
their ﬁrst symptomatic PAF episode ,6 months prior to inclusion
compared with 5.8% of controlled patients). As such, improve-
ments in QoL in the uncontrolled group may be related to patients
adjusting to their AF. It is beyond the scope of this study to directly
attribute improvements in QoL to a speciﬁc drug effect.
Another key limitation of the study is the inability to assess all
symptomatic PAF episodes objectively (ECG). In an attempt to
collect information on all symptomatic PAF episodes, inquiry and
patient diaries were also used to record symptomatic PAF based
on subjective evaluations without the objective conﬁrmation of
an ECG. Some analyses combined objective and subjective assess-
ments (as indicated in the description of the analyses) and this
should be taken into consideration when interpreting results.
Conclusion
In this study, patients with uncontrolled symptomatic PAF at base-
line had an inferior QoL to patients with controlled symptomatic
PAF. Following treatment with controlled-release ﬂecainide
acetate, their QoL improved to a level comparable to controlled
patients. The use of QoL questionnaires to assist with therapeutic
decision-making and follow-up evaluation for patients with symp-
tomatic PAF could prove valuable.
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